News Boehringer, Brainomix plan new trial of lung fibrosis AI Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
News Boehringer bags FDA okay for new pulmonary fibrosis drug Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?
News Ten years on, Roche jettisons InterMune and Esbriet in US It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.
News Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.
News Pliant slumps on decision to pause lung disease drug trial Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.